HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Unanue, E. R. Articles by Dixon, F. J. Search for Related Content PubMed Articles by Unanue, E. R. Articles by Dixon, F. J.

Nephrotoxic Serum Nephritis in Complement Intact and Deficient Mice¹

From the Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California

Abstract

In 1962, Rosenberg and Tachibana reported that certain strains of mice lacked hemolytic complement (C') activity (1). The lack of C' is genetically controlled (2) and related to the absence of a migrating globulin (3, 4). The C' deficient mice are able to make an immune response to this globulin, which they lack but which is present in C' intact strains (3, 4). Nilsson and Müller-Eberhard have identified the deficient globulin as analogous to human _1F-globulin (5) which in the human C' sequence is C'5. The C' deficient mice lack C'5 activity (6) while having normal C'1,4 and 2 activities (7) and _1c-globulin (C'3) (8, 9).

C' deficient mice have normal phagocytosis of bacteria (10), are able to reject allogeneic skin grafts (11) and develop Arthus reactions (8, 12). They may develop passive cutaneous anaphylaxis with rabbit antibody but only when large amounts are employed (13).

Footnotes

This is Publication No. 179 from the Department of Experimental Pathology, Scripps Clinic and Research Foundation, La Jolla, California.

This work was supported by United States Public Health Service Grant 7007-01 and AEC Contract AT(O4-3) (410).

² Present address: Division of Immunology, National Institute for Medical Research, Mill Hill, London, England.

³ Present address: Division of Immunology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.